Revive Therapeutics Ltd
OTCQB:RVVTFView on Canadian Exchange

  • LAST PRICE
    0.0068
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.0001/ 100
  • Ask / Lots
    0.0252/ 100
  • Open / Previous Close
    --- / 0.0068
  • Day Range
    ---
  • 52 Week Range
    0.0055
    0.0360
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

      Show headlines and story abstract

    • 22 hours ago by Dow Jones
      Companies Mentioned: RVV

      Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

      TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, medical countermeasures and rare disorders, today announced the publication of a scientific article demonstrating the potential of psilocybin as a novel therapeutic approach in stroke. The publication, entitled, "Neuroprotective effects of psilocybin in a rat model of stroke," is published in BMC Neuroscience and is available here.

  • Oct 31, 2024

      Show headlines and story abstract

    • 7:30AM ET on Thursday Oct 31, 2024 by Dow Jones
      Companies Mentioned: RVV

      Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

      TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada -- Suffield Research Centre ("DRDC"), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury.

Peers Headlines

No documents available